AstraZeneta resumes clinical trials of the new crown vaccine in the UK

BEIJING, Sept. 14 (Xinhua
) -- AstraZeneza Pharmaceuticals and Oxford University announced Wednesday that they have resumed clinical trials of the new crown vaccine AZD1222, which they are working together to develop, after obtaining permission from British regulators.
(Reuters) - AstraZeneza has suspended clinical trials of the AZD1222 vaccine after a British subject developed a "suspected serious adverse reaction," The World Health Organization's chief scientist, Sumia Swaminathan, said on Monday.
AstraZeneta said on its website on September 12th that it had voluntarily suspended clinical trials of its new crown vaccine in multiple places around the world in order for an independent international
to review the safety data. Still, the vaccine is expected to be used "by the end of this year, early next year." Now that the review process has been completed, vaccine safety has been
the Independent Society and the UK Medicines and Healthcare Products Authority. The company will continue to work with health regulators in other countries to determine as soon as possible when to resume clinical trials of vaccines in those countries.
University of Oxford also confirmed the news of the restart of clinical trials of the vaccine, saying: "There are 18,000 people worldwide who have been vaccinated against the vaccine in clinical trials, and in such a large trial, some subjects are unwell as expected, and researchers will carefully assess each case to ensure the safety of the vaccine."
AstraZeneta and Oxford University said on the 12th that in order to protect the privacy of subjects, will not disclose more information about patients with the disease, but will update all trial researchers and participants in accordance with clinical trials and regulatory standards, and will disclose this information in clinical registries around the world.
AZD1222 vaccine is one of nine new crown vaccines currently in the advanced stages of Phase III. clinical trials. The vaccine uses chimpanzee adenovirus as a vector to recombine the new coronavirus, which infects chimpanzees and contains genetic material for the new coronavirus prickly protein. When the body is vaccinated, it produces surface prickly proteins that stimulate the immune system to attack the new coronavirus.
is understood to have launched Phase III clinical trials in the United States on August 31st, with plans to recruit 30,000 subjects, small clinical trials in the United Kingdom, Brazil and South Africa, and clinical trials in Japan and Russia, with an expected 50,000 subjects worldwide.
Although the AZD1222 vaccine is still in clinical trials, authorities and companies in the European Union, Australia and other places have announced agreements with AstraZeneta to obtain the vaccine or its production license after the success of the clinical trial.